Lifetime Health Consequences and Cost-effectiveness of Rosiglitazone in Combination with Metformin for the Treatment of Type 2 Diabetes in Spain.
- Published in:
- PharmacoEconomics, 2006, p. 49, doi. 10.2165/00019053-200624001-00005
- By:
- Publication type:
- Article